--- title: "Polaryx Therapeutics (PLYX) news: reverse split and going concern" url: "https://aibio.space/companies/polaryx-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PLYX reverse split, going concern, IPO and offering news: Polaryx completes one-for-four reverse stock split ahead of Nasdaq listing." --- PLYX Polaryx Therapeutics, Inc. NASDAQ · United States # Polaryx Therapeutics (PLYX) news PLYX reverse split, going concern, IPO and offering news Distress · 2026-08-13 ## [Polaryx reports $11.5 million cash, funding into early 2027 and going-concern doubt](https://aibio.space/news/polaryx-reports-11-5-million-cash-funding-early-2027-going-concern/) The company says its cash lasts through the first quarter of 2027 and it will need more capital after that. SOTERIA is due to start in the second half of 2026. ## Latest Polaryx Therapeutics news 1. 2026-05-28 Financings [Polaryx closes $10 million private placement with about 35 investors](https://aibio.space/news/polaryx-closes-10-million-private-placement-about-35-investors/) Prices ran from $3.70 to $4.10 a share depending on commitment size. MStone Partners, the largest holder, bought $360,000 of stock. 2. 2026-02-02 Listings [Polaryx begins Nasdaq trading through a direct listing](https://aibio.space/news/polaryx-begins-nasdaq-trading-through-direct-listing/) Polaryx began trading on Nasdaq on February 2, 2026 without an underwriter, and the company received no money from the listing. 3. 2026-01-12 Listings [Polaryx completes one-for-four reverse stock split ahead of Nasdaq listing](https://aibio.space/news/polaryx-completes-one-four-reverse-stock-split-ahead-nasdaq-listing/) Polaryx's 1-for-4 reverse split took effect on January 12, 2026, ahead of a Nasdaq direct listing that raised no money for the company. ## Polaryx Therapeutics at a glance - **Ticker**: PLYX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $11.5 million ### Related companies - [Cardiff Oncology](https://aibio.space/companies/cardiff-oncology/) NASDAQ: CRDF - [MiMedx Group](https://aibio.space/companies/mimedx/) NASDAQ: MDXG - [Organogenesis Holdings](https://aibio.space/companies/organogenesis/) NASDAQ: ORGO - [Bone Biologics](https://aibio.space/companies/bone-biologics/) NASDAQ: BBLG - [Endovia Health Sciences](https://aibio.space/companies/endovia-health-sciences/) AMEX: EDVA - [Nutriband](https://aibio.space/companies/nutriband/) NASDAQ: NTRB - [Apollomics](https://aibio.space/companies/apollomics/) NASDAQ: APLM - [Dermata Therapeutics](https://aibio.space/companies/dermata-therapeutics/) NASDAQ: DRMA ### Also on NASDAQ - [First Tracks Biotherapeutics](https://aibio.space/companies/first-tracks-biotherapeutics/) TRAX - [Aytu BioPharma](https://aibio.space/companies/aytu-biopharma/) AYTU - [Keros Therapeutics](https://aibio.space/companies/keros-therapeutics/) KROS - [Tenax Therapeutics](https://aibio.space/companies/tenax-therapeutics/) TENX - [MAXCYTE, INC.](https://aibio.space/companies/maxcyte/) MXCT - [Kazia Therapeutics](https://aibio.space/companies/kazia-therapeutics/) KZIA ## Polaryx Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$6.3 million](https://www.sec.gov/Archives/edgar/data/2075320/000121390026033064/) | [$2.8 million](https://www.sec.gov/Archives/edgar/data/2075320/000121390026033064/) | | Net income (loss) | [-$9.0 million](https://www.sec.gov/Archives/edgar/data/2075320/000121390026033064/) | [-$30.4 million](https://www.sec.gov/Archives/edgar/data/2075320/000121390026033064/) | | Cash from operations | [-$3.9 million](https://www.sec.gov/Archives/edgar/data/2075320/000121390026033064/) | [-$2.6 million](https://www.sec.gov/Archives/edgar/data/2075320/000121390026033064/) | | Cash and equivalents | [$5.1 million](https://www.sec.gov/Archives/edgar/data/2075320/000121390026089118/) | [$4.6 million](https://www.sec.gov/Archives/edgar/data/2075320/000121390026033064/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $11.5 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Polaryx Therapeutics Did Polaryx Therapeutics do a reverse stock split? Our latest story on this, dated Jan 12, 2026: "Polaryx completes one-for-four reverse stock split ahead of Nasdaq listing". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/polaryx-completes-one-four-reverse-stock-split-ahead-nasdaq-listing/). Has Polaryx Therapeutics issued a going-concern warning? Our latest story on this, dated Aug 13, 2026: "Polaryx reports $11.5 million cash, funding into early 2027 and going-concern doubt". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/polaryx-reports-11-5-million-cash-funding-early-2027-going-concern/). When did Polaryx Therapeutics go public? Our latest story on this, dated Feb 2, 2026: "Polaryx begins Nasdaq trading through a direct listing". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/polaryx-begins-nasdaq-trading-through-direct-listing/). Has Polaryx Therapeutics raised money recently? Our latest story on this, dated May 28, 2026: "Polaryx closes $10 million private placement with about 35 investors". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/polaryx-closes-10-million-private-placement-about-35-investors/). What is the ticker symbol of Polaryx Therapeutics? Polaryx Therapeutics, Inc. trades under the ticker PLYX on NASDAQ. Where is Polaryx Therapeutics listed? Polaryx Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Polaryx Therapeutics? The SEC Central Index Key (CIK) for Polaryx Therapeutics, Inc. is 2075320. Its filings are on SEC EDGAR. How many shares does Polaryx Therapeutics have outstanding? 49,845,993 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Polaryx Therapeutics listed under? Our directory records Polaryx Therapeutics, Inc. under United States. What does Polaryx Therapeutics do? Our directory classifies Polaryx Therapeutics, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline. What is the ISIN of Polaryx Therapeutics? The ISIN recorded for Polaryx Therapeutics, Inc. is US73110F1003. Does aibio.space cover Polaryx Therapeutics? aibio.space lists Polaryx Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Polaryx Therapeutics incorporated? SEC records list its state or country of incorporation as WY. Is Polaryx Therapeutics profitable? Polaryx Therapeutics, Inc. reported a net loss of $9.0 million for the fiscal year ended Dec 31, 2025, and used $3.9 million of cash in operations, per its annual report to the SEC. How much does Polaryx Therapeutics spend on research and development? $6.3 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Polaryx Therapeutics Members talk about Polaryx Therapeutics (PLYX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Polaryx Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-09-01 Leadership The new chief medical officer appointment became effective. [Source](https://www.sec.gov/Archives/edgar/data/2075320/000121390026096235/ea0303928-8k_polaryx.htm) 2. 2026-08-13 Going concern The quarterly report retained substantial doubt alongside an estimate that cash would fund operations through the first quarter of 2027. [Source](https://www.sec.gov/Archives/edgar/data/2075320/000121390026089118/ea0301429-10q_polaryx.htm) 3. 2026-07-19 Leadership The chief medical officer resigned; the company said its disclosed development timelines were not expected to change. [Source](https://www.sec.gov/Archives/edgar/data/2075320/000121390026080041/ea0298434-8k_polaryx.htm) 4. 2026-05-28 Financing The private placement closed for $10 million gross. [Source](https://www.sec.gov/Archives/edgar/data/2075320/000121390026062155/ea0291692-8k_polaryx.htm) 5. 2026-05-28 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/2075320/000121390026062155/ea029169201ex99-1.htm) 6. 2026-05-27 Financing Polaryx signed the common-stock private-placement purchase agreement. [Source](https://www.sec.gov/Archives/edgar/data/2075320/000121390026062155/ea0291692-8k_polaryx.htm) 7. 2026-03-24 Going concern The annual report disclosed substantial doubt about continuing operations. [Source](https://www.sec.gov/Archives/edgar/data/2075320/000121390026033064/ea0281719-10k_polaryx.htm) 8. 2026-03-24 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/2075320/000121390026033064/ea0281719-10k_polaryx.htm) 9. 2026-01-12 Reverse split Polaryx implemented the one-for-four common-stock consolidation. [Source](https://www.sec.gov/Archives/edgar/data/2075320/000121390026033064/ea0281719-10k_polaryx.htm) 10. 2025-10-31 Financing The later crowdfunding update reported $45,024.70 aggregate proceeds and 68,756 securities. [Source](https://www.sec.gov/Archives/edgar/data/2075320/000121390025104723/xslC_X01/primary_doc.xml) 11. 2025-10-27 Financing A crowdfunding progress update reported $23,014.60 and 35,301 securities at the close of the offering; a later update reported an aggregate of $45,024.70. [Source](https://www.sec.gov/Archives/edgar/data/2075320/000121390025102529/xslC_X01/primary_doc.xml) ## Investor questions about Polaryx Therapeutics ### Did the direct listing itself provide new issuer cash? The prospectus says the company receives no proceeds from registered-holder resales. Listing and a new issuer cash raise are distinct. [Source](https://www.sec.gov/Archives/edgar/data/2075320/000121390026010761/ea0251239-09.htm) ### When did public trading begin? The annual report states that trading began on 2026-02-02 on the Nasdaq Capital Market. [Source](https://www.sec.gov/Archives/edgar/data/2075320/000121390026033064/ea0281719-10k_polaryx.htm) ### What was the latest reported cash balance? Cash and equivalents were $11.542 million at 2026-06-30. Source balance-sheet amounts are in thousands of dollars. [Source](https://www.sec.gov/Archives/edgar/data/2075320/000121390026089118/ea0301429-10q_polaryx.htm) ### What funding horizon did management state? The quarterly report projected funding through the first quarter of 2027. It is a plan-based estimate rather than an exact exhaustion date. [Source](https://www.sec.gov/Archives/edgar/data/2075320/000121390026089118/ea0301429-10q_polaryx.htm) ### Did the latest report contain substantial doubt? Yes. The quarterly liquidity note says the company's conditions raise substantial doubt about its ability to continue as a going concern for twelve months from the date the statements were available to be issued. [Source](https://www.sec.gov/Archives/edgar/data/2075320/000121390026089118/ea0301429-10q_polaryx.htm) ### Did Polaryx complete a private placement? The company reported closing its common-share placement on 2026-05-28 for $10 million gross. [Source](https://www.sec.gov/Archives/edgar/data/2075320/000121390026062155/ea0291692-8k_polaryx.htm) ### Was a reverse split completed? The company completed a one-for-four common-stock split effective on 2026-01-12. Historical share data in the cited reports are adjusted for it. [Source](https://www.sec.gov/Archives/edgar/data/2075320/000121390026033064/ea0281719-10k_polaryx.htm) ### Who audits Polaryx? The annual report is signed by Grant Thornton LLP, which states service since 2024. [Source](https://www.sec.gov/Archives/edgar/data/2075320/000121390026033064/ea0281719-10k_polaryx.htm) ### How much did the latest crowdfunding update report? The later progress report states an aggregate $45,024.70 and 68,756 securities. The earlier progress amount is not added to that aggregate. [Source](https://www.sec.gov/Archives/edgar/data/2075320/000121390025104723/xslC_X01/primary_doc.xml) ### Does the employee-plan registration establish cash proceeds? No. The fee table describes shares available for future plan issuance; it does not announce a completed subscription receipt. [Source](https://www.sec.gov/Archives/edgar/data/2075320/000121390026081404/ea029812301ex-fee.htm) ### Is material litigation disclosed in the latest quarter? The company says it was not party to material legal proceedings at that time. This is a dated issuer statement, not a comprehensive independent court search. [Source](https://www.sec.gov/Archives/edgar/data/2075320/000121390026089118/ea0301429-10q_polaryx.htm) ### Can the Mstone and CEO holdings be added together? No. The proxy attributes overlapping voting interests in the Mstone entities to the CEO. Adding both rows would count the same interests twice. [Source](https://www.sec.gov/Archives/edgar/data/2075320/000121390026082339/ea0298291-01.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:PLYX on TradingView](https://www.tradingview.com/symbols/NASDAQ-PLYX/). ## SEC filings and registration - **SEC name**: Polaryx Therapeutics, Inc. - **CIK**: 2075320 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: PLYX (Nasdaq) - **State or country of incorporation**: WY - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 140 EAST RIDGEWOOD AVENUE, PARAMUS, NJ, 07652 - **Phone**: 201-940-7236 - **Shares outstanding**: 49,845,993 as of 2026-07-31 (10-Q filed 2026-08-13) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/2075320/000121390026099416/ea0305352-8k_polaryx.htm) filed 2026-09-14 - [8-K](https://www.sec.gov/Archives/edgar/data/2075320/000121390026096235/ea0303928-8k_polaryx.htm) filed 2026-09-01 - [10-Q](https://www.sec.gov/Archives/edgar/data/2075320/000121390026089118/ea0301429-10q_polaryx.htm) filed 2026-08-13 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/2075320/000121390026082339/ea0298291-01.htm) filed 2026-07-28 - [8-K](https://www.sec.gov/Archives/edgar/data/2075320/000121390026080041/ea0298434-8k_polaryx.htm) filed 2026-07-21 - [8-K](https://www.sec.gov/Archives/edgar/data/2075320/000121390026078912/ea0298274-8k_polaryx.htm) filed 2026-07-17 - [8-K](https://www.sec.gov/Archives/edgar/data/2075320/000121390026062155/ea0291692-8k_polaryx.htm) filed 2026-05-28 - [10-Q](https://www.sec.gov/Archives/edgar/data/2075320/000121390026056973/ea0289299-10q_polaryx.htm) filed 2026-05-15 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002075320), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Polaryx Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PLYX, recorded under United States. The directory classifies it as Biopharma / pharmaceuticals. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Polaryx Therapeutics, Inc. - **Ticker**: PLYX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biopharma / pharmaceuticals - **ISIN**: US73110F1003 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-PLYX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/polaryx-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Polaryx Therapeutics (PLYX) news: reverse split and going concern", 2026-10-31, https://aibio.space/companies/polaryx-therapeutics/